What Was Hyped, and What Fell Out of Favor, This Year in Biotech
Luke Timmerman Every year, Science magazine profiles its “Breakthrough of the Year.” People get excited. But what many readers don’t fully appreciate is that these discoveries—at least in …
View ArticleEleven Prices IPO Below Projected Range, Grabs $50M
Ben Fidler Eleven Biotherapeutics wants to prove that a drug it’s developing can go toe to toe with Allergan’s big-selling dry eye disease drug, Restasis. Wall Street, however, was tepid …
View ArticleConcert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share
Ben Fidler What’s it worth to add a little deuterium to drugs to boost their abilities? In Wall Street’s eyes, about $14 per share. Lexington, MA-based Concert Pharmaceuticals will debut …
View ArticleWhat’s Hot in Boston Biotech: Here’s the Agenda for April 16
Ben Fidler There are plenty of reasons Wall Street is jittery that a biotech bubble is about to pop. But this bull market formed for a reason: innovative new science …
View ArticleAgios’s Blood Cancer Drug Shines in First Clinical Test
Ben Fidler When David Schenkein left Genentech to lead Agios Pharmaceuticals in 2009, part of the draw was the fact that the Cambridge, MA-based startup was positioning itself as a …
View Article7 Takeaways From “What’s Hot in Boston Biotech”
Ben Fidler Sometimes it takes a contrarian viewpoint, and a little guts, to get a scientific idea off the ground. Other times an idea can be so enthralling that venture …
View ArticleGet a Window on the Innovation Future at Boston 2034 on June 10
Robert Buderi It’s gotten to be an easy rant—chastising entrepreneurs for not thinking big enough. But that’s plain wrong, especially in the Boston area. New England visionaries have long been …
View ArticleModerna, Changing Its Identity, Plots Army of mRNA Spinouts
Ben Fidler Kendall Square has found its newest biotech incubator. Moderna Therapeutics just had no idea it’d be the one running it. Moderna, the high-flying, privately held startup that raised …
View ArticleOne More Thought From Boston 2034: Tech + Biotech + Cleantech = ?
Gregory T. Huang When we assembled some of the top business leaders and thinkers across New England for Boston 2034 last week, I noticed a high-level theme: we were trying …
View ArticleThe Second Xconomy Boston Healthcare Summit: Request An Invitation
Robert Buderi A lot has happened in healthcare over the past year. For starters, Healthcare.gov, the federal website for buying insurance under the Affordable Care Act, has gone up, …
View ArticleWith Crossover Cash, Seres Health Aims For Big Microbiome Milestones
Alex Lash Seres Health of Cambridge, MA, announced two big steps Tuesday. First, it says it has raised $48 million in a Series C round from public investors, which is (Read more...)
View ArticlePhytonix Turns Photosynthetic Bacteria Into Tiny Chemical Factories
Frank Vinluan Ambitions for biologically sourced fuels bump up against the reality that making chemicals and fuels from organic material is still generally more expensive. One company is hoping to...
View ArticleWith Massive Venture Round, Moderna Has $450M Reasons to Stay Private
Ben Fidler Investment dollars have been pouring into private and public biotechs, but nothing can quite match Moderna Therapeutics. Cambridge, MA-based Moderna says it has raised a $450 million...
View ArticleWith $21M, Retooled Blend Whips up Mini-Smart Bombs For Cancer
Ben Fidler Sometimes in biotech, you go in with one plan, and an unexpected discovery changes everything. That’s the case with Blend Therapeutics, which has morphed into a company trying (Read more...)
View ArticleJ.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex
Alex Lash The word “story” gets ill treatment at events like the J.P. Morgan Healthcare Conference. It often means an elevator pitch from a harried CEO to a distracted (Read more...)
View Article
More Pages to Explore .....